Business Context and Reporting Period
This Form 8-K Current Report is filed by 180 Life Sciences Corp. (not Forum Markets Inc.) for the reporting date of July 24, 2025. The filing details the results of the Company's 2025 Annual Meeting of Stockholders, where several key corporate governance and equity plan proposals were voted upon and approved.
Key Financial Metrics
This filing is a current report regarding corporate actions and does not contain financial performance data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Corporate Actions
- Authorized Share Increase: Stockholders approved an amendment to the Certificate of Incorporation increasing authorized common stock from 100,000,000 to 1,000,000,000 shares. This amendment became effective immediately upon filing with the Delaware Secretary of State on July 24, 2025.
- Equity Incentive Plans:
- 2022 Omnibus Incentive Plan (OIP): Approved the Fourth Amendment, increasing the share pool by 4,000,000 shares to an initial total of 5,000,000 shares. The plan includes an annual increase mechanism of 10% of outstanding shares for seven years starting in 2026.
- 2025 Option Incentive Plan: Approved the adoption of this new plan with a pool of 1,000,000 shares. All 1,000,000 awards under this plan have already been granted. Stockholder approval rendered these previously granted options exercisable.
- Reverse Stock Split Authority: Stockholders granted the Board discretionary authority to effect a reverse stock split of common stock at a ratio between 1-for-4 and 1-for-40 at any time prior to July 24, 2026.
- Director Elections: Lawrence Steinman, M.D., and Stephen H. Shoemaker were elected as Class I directors for two-year terms.
Voting Results and Management Commentary
Stockholders representing 2,389,696 shares (39.57% of voting shares) were present, constituting a quorum. All eight proposals presented were approved with significant majorities:
- Proposal 1 (Directors): Both nominees received over 99% "For" votes.
- Proposal 2 (OIP Amendment): Approved with 2,363,243 "For" votes vs. 24,592 "Against".
- Proposal 3 (2025 Option Plan): Approved with 2,379,325 "For" votes vs. 8,405 "Against".
- Proposal 4 (Executive Compensation): Advisory vote approved with 2,381,756 "For" votes vs. 6,166 "Against".
- Proposal 5 (Reverse Split Authority): Approved with 2,381,839 "For" votes vs. 6,199 "Against".
- Proposal 6 (Authorized Shares): Approved with 2,379,503 "For" votes vs. 8,343 "Against".
- Proposal 7 (Auditor Ratification): M&K CPAs, PLLC ratified with 2,388,703 "For" votes vs. 712 "Against".
The filing notes that no adjournment of the meeting was necessary to solicit additional proxies.
Investor Verification Checklist
- Verify the effective date of the authorized share increase (1 billion shares) in the Delaware Secretary of State records.
- Review the full text of the Fourth Amendment to the 2022 Omnibus Incentive Plan (Exhibit 10.2) to understand specific vesting and performance terms.
- Confirm the status of the 1,000,000 options granted under the 2025 Option Plan and their current exercisability.
- Monitor future Board announcements regarding the potential execution of the reverse stock split authority granted in Proposal 5.
- Check subsequent filings for any changes to the capital structure resulting from the new share authorization.